Abstract
The Bcl-2 family includes 26 proteins involved in apoptosis. Cancer cells can develop the ability to avoid apoptosis through the upregulation and/or down regulation of such proteins Bax, Bcl-xL or Mcl-1, especially during chemoresistance progress. These proteins engaged in a network of dynamic interactions that control apoptosis triggering have become attractive therapeutic targets in cancers including melanoma. Among them, the Bax/Bcl-xL interaction appears critical in maintaining mitochondria integrity. Therefore a series of mixed polyphenol-heterocyclic molecules, were rationally designed by molecular docking as Bax/Bcl-xL inhibitors. It has been screened against B16-F10 melanoma cancer cells for a preliminary investigation of their cytotoxicity. All these compounds exhibited a significant cytotoxicity against these cancer cells, in the 0.3-6 M range. A pyrazole-type molecule, which had a submicromolar IC50 value with an excellent selectivity index (14), is the most promising derivative for further development.
Keywords: Apoptosis, Bcl-xL, B-16-F10 cells, BRET, cancer, melanoma, pyrazoles.
Medicinal Chemistry
Title:Preliminary Studies on the Activity of Mixed Polyphenol-Heterocyclic Systems Against B16-F10 Melanoma Cancer Cells
Volume: 12 Issue: 5
Author(s): Duc Duy Vo, Isabelle Rouaud, Francoise Le Devehat, Fabien Gautier, Sophie Barillé-Nion, Philippe Juin, Nicolas Levoin, Joël Boustie and René Grée
Affiliation:
Keywords: Apoptosis, Bcl-xL, B-16-F10 cells, BRET, cancer, melanoma, pyrazoles.
Abstract: The Bcl-2 family includes 26 proteins involved in apoptosis. Cancer cells can develop the ability to avoid apoptosis through the upregulation and/or down regulation of such proteins Bax, Bcl-xL or Mcl-1, especially during chemoresistance progress. These proteins engaged in a network of dynamic interactions that control apoptosis triggering have become attractive therapeutic targets in cancers including melanoma. Among them, the Bax/Bcl-xL interaction appears critical in maintaining mitochondria integrity. Therefore a series of mixed polyphenol-heterocyclic molecules, were rationally designed by molecular docking as Bax/Bcl-xL inhibitors. It has been screened against B16-F10 melanoma cancer cells for a preliminary investigation of their cytotoxicity. All these compounds exhibited a significant cytotoxicity against these cancer cells, in the 0.3-6 M range. A pyrazole-type molecule, which had a submicromolar IC50 value with an excellent selectivity index (14), is the most promising derivative for further development.
Export Options
About this article
Cite this article as:
Duy Vo Duc, Rouaud Isabelle, Le Devehat Francoise, Gautier Fabien, Barillé-Nion Sophie, Juin Philippe, Levoin Nicolas, Boustie Joël and Grée René, Preliminary Studies on the Activity of Mixed Polyphenol-Heterocyclic Systems Against B16-F10 Melanoma Cancer Cells, Medicinal Chemistry 2016; 12 (5) . https://dx.doi.org/10.2174/1573406412666160129104603
DOI https://dx.doi.org/10.2174/1573406412666160129104603 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy
Current Cancer Drug Targets The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Inhibiting Matrix Metalloproteinases, an Old Story with New Potentials for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Immunobiologic Agents in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Use of Interferons in Respiratory Diseases
Current Respiratory Medicine Reviews Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design Mechanistic Insight of Drug Resistance with Special Focus on Iron in Estrogen Receptor Positive Breast Cancer
Current Pharmaceutical Biotechnology Endogenous Retroelements in Cellular Senescence and Related Pathogenic Processes: Promising Drug Targets in Age-Related Diseases
Current Drug Targets Sam Domains in Multiple Diseases
Current Medicinal Chemistry The Role of Integrins in Glioma Biology and Anti-Glioma Therapies
Current Pharmaceutical Design Novel Hybrid Molecules of Quinazoline Chalcone Derivatives: Synthesis and Study of in vitro Cytotoxic Activities
Letters in Drug Design & Discovery Cytotoxic and Apoptogenic Activity of a Methanolic Extract from the Marine Invertebrate Ciona intestinalis on Malignant Cell Lines
Medicinal Chemistry Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review
Current Drug Targets Curcumin Therapeutic Modulation of the Wnt Signaling Pathway
Current Pharmaceutical Biotechnology A Prooxidant Mechanism for the Anticancer and Chemopreventive Properties of Plant Polyphenols
Current Drug Targets Changes of Gene Expression in the Developing Brain by Acute Ethanol Exposure
Current Psychopharmacology Lack of Interaction of the NMDA Receptor Antagonists Dextromethorphan and Dextrorphan with P-Glycoprotein
Current Drug Metabolism Beneficiary and Adverse Effects of Phytoestrogens: A Potential Constituent of Plant-based Diet
Current Pharmaceutical Design Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease
Current Drug Metabolism MET and ALK as Targets for the Treatment of NSCLC
Current Pharmaceutical Design